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Abstract
Gout affects more than 1% of adults in the USA, and it is the most
common form of inflammatory arthritis among men. Accumulating
data support an increase in the prevalence of gout that is potentially
attributable to recent shifts in diet and lifestyle, improved medical
care, and increased longevity. There are both nonmodifiable and
modifiable risk factors for hyperuricemia and gout. Nonmodifiable
risk factors include age and sex. Gout prevalence increases in
direct association with age; the increased longevity of populations
in industrialized nations may contribute to a higher prevalence of
gout through the disorder’s association with aging-related diseases
such as metabolic syndrome and hypertension, and treatments for
these diseases such as thiazide diuretics for hypertension. Although
gout is considered to be primarily a male disease, there is a more
equal sex distribution among elderly patients. Modifiable risk factors
for gout include obesity, the use of certain medications, high purine
intake, and consumption of purine-rich alcoholic beverages. The
increasing prevalence of gout worldwide indicates that there is an
urgent need for improved efforts to identify patients with
hyperuricemia early in the disease process, before the clinical
manifestations of gout become apparent.
Introduction
Assessing the incidence and prevalence of gout is
challenging because of its episodic nature. In the USA gout
estimates vary, depending on the population being described.
For example, male veterans are at heightened risk for
developing gout because of their numerous risk factors, as
seen in the Normative Aging Study conducted by the US
Department of Veterans Affairs (Fig. 1) [1]. In contrast, white
male physicians exhibited a cumulative incidence of gout over
a 30-year period of approximately 8.6%, with 5.9% having
primary gout (gout without a history of diuretic use) [2].
African-American physicians may have an even higher rate of
gout [3]. Although data on physicians cannot accurately be
generalized to the public, doctors do more accurately self-
report suspected gout than the lay population, from whom
many of the other gout estimates were derived.
The Rochester epidemiology study [4] has reported on the
change in gout incidence over time. Comparing men and
women from two cohorts – one from 1977 to 1978 and
another from 1995 to 1996 – Arromdee and coworkers
found that the age- and sex-adjusted annual incidence rate
for primary gout in the USA rose from 20.2/100,000 persons
to 45.9/100,000 persons; no change in the incidence of
secondary gout related to thiazide diuretic therapy was
observed. Gout has also been shown to increase somewhat
linearly over a person’s lifespan. This perceived rise in gout
prevalence is primarily associated with an aging population,
but it is also potentially associated with a number of changing
societal trends. Based on self-reported gout from the
National Health Interview Survey [5], in 1992 about 2 million
people were characterized as having gout. In 1996 there
were increases in gout incidence of up to 4.6% in men and
2% in women among those in the higher risk age range of 65
years or older, leading to an estimated overall prevalence of
between 0.5% and 1%.
The prevalence of gout also appears to be rising in certain
populations. A multicenter study conducted in the UK in
1991 found that the prevalence of gout had increased
threefold compared with estimates from the 1970s [6]. In a
1999 examination of gout epidemiology from the UK General
Practice Research Database [7], gout prevalence was found
to be approximately 2% among men and about 1% among
men and women combined. Prevalence was highest among
those aged 75–84 years; among the men gout incidence
approached 8%. Gout prevalence varies substantially by
geographic region. In New Zealand among the Maoris gout is
relatively endemic with prevalence estimated as high as 5%
[8,9]. The prevalence of gout in particular geographic regions
suggests that both genetic factors and environmental factors
predispose individuals to developing gout [10].
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The varied methods of reporting epidemiological data on gout
and the sometimes imperfect data sources available make it
difficult to document the public health impact accurately. In
the Sudbury study [11], for example, in as many as half of the
patients who claimed to have gout, this could not be
confirmed by history and physical examination. Although it is
best to rely on a crystal diagnosis to confirm cases of gout,
this is not practical at the population level.
Why is the prevalence of gout potentially rising? One reason
may be changes in gout risk factors, not the least of which is
increased longevity. As Americans get older and heavier,
there has been a concordant rise in the prevalence of
hypertension [12,13]. Both the metabolic syndrome and
hypertension have a strong association with gout [14,15]
(see below), and treatments for hypertension (e.g. thiazide
diuretics) can result in the development of secondary gout
[16]. Results from the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack (ALLHAT) trial [17] have
led to the recommendation that diuretics be given as first-line
therapy in most patients with hypertension; some therefore
speculate that the incidence of secondary gout related to
diuretic use is likely to grow in the near future. The ubiquitous
use of low-dose aspirin for the prevention of cardiovascular
disease may be another reason for the rise in gout prevalence
[18,19].
Nonmodifiable risk factors for gout
Age
The prevalence of gout increases in direct association with
age; therefore, the increased longevity of populations in
industrialized nations may contribute to a higher prevalence
of gout through the disorder’s association with age-related
diseases (e.g. metabolic syndrome and hypertension) and
treatments for aging-related diseases (e.g. thiazide diuretics)
[14-16]. Moreover, the prevalence of the clinical manifesta-
tions of gout increases with the duration of hyperuricemia.
Thus, elderly patients with longstanding hyperuricemia are
more likely to present with the signs and symptoms of gout. In
one study conducted by Wallace and coworkers [20],
individuals older than 75 years exhibited an increase in the
rate of gout from 21/1000 persons in 1990 to 41/1000
persons in 1999, and in the 65–74 year age group the
increase was from 21/1000 to 24/1000 persons from 1990
to 1992 to more than 31/1000 from 1997 to 1999. In
contrast, prevalence rates in persons younger than 65 years
remained consistently low throughout the study. In those
older than 75 years, the prevalence per 1000 is quite sizable
compared with that in younger age ranges; these findings are
similar to some of the data from the General Practice
Research Database (discussed below).
Sex
Clinically, gout is often considered a male disease. Although
gout prevalence has increased in both sexes, among patients
younger than 65 years men have a fourfold greater prevalence
than women [20]. However, gout in the elderly has a more
equal sex distribution, most likely reflecting the loss of the
uricosuric effect of estrogen following the menopause. In
patients older than 65 years, the sex gap narrows to one
woman to every three men with gout and/or hyperuricemia
(3:1 ratio). With the declining use of estrogen therapy, the
percentage of elderly female patients with gout may increase.
Modifiable gout risk factors
Serum urate
Serum urate level is the most important risk factor for gout. In
the Normative Aging Study [1], 2046 initially healthy
participants were followed for 14.9 years. Those with baseline
serum urate levels of ≥9 mg/dl had a 22% cumulative
incidence of gout over a 6-year period. Among patients with
urate levels of ≤7.0 mg/dl and 7.0–8.9 mg/dl, the annual
incidences of gouty arthritis were 0.5% and 0.1%,
respectively (Fig. 1). Large percentages of people in the USA
[21] and Japan [22], men in particular, have urate levels above
the solubility threshold of approximately 6.7 mg/dl. In patients
with gout who are older than 60 years, however, about half are
women and the prevalence in women increases as they age.
Medications
Gout is associated with a number of different medications,
including diuretics (noted above), low-dose aspirin, and drugs
that are commonly used in organ transplantation.
Currently, approximately 46% of women and 59% of men
who are at high risk for cardiovascular events take aspirin.
Many persons at low risk for cardiovascular events also take
Figure 1
Cumulative incidence of gouty arthritis by prior urate levels. Reproduced
from [1]. Copyright 1987 with permission from Excerpta Medica Inc.Page 3 of 7
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low-dose aspirin in response to the positive publicity
surrounding the prevention trials and guidelines [18]. Aspirin
has been shown to have a bimodal effect on renal handling of
uric acid. At high dosages (>3 g/day) aspirin is uricosuric,
whereas at low dosages (1–2 g/day) it causes uric acid
retention [23]. At 75 mg/day aspirin resulted in a 15%
decrease in the rate of uric acid excretion (P = 0.045) and a
small but significant increase in serum levels of uric acid
(P = 0.009) [19]. These effects declined with increasing
dosages of aspirin. Concomitant use of diuretics exacerbated
the effects of aspirin on uric acid levels.
Renal and other major organ transplants
Hyperuricemia and gout are common complications of renal
and other major solid-organ transplants. Gouty joint damage
is accelerated in transplant patients with hyperuricemia
compared with patients with primary hyperuricemia, and gout
is frequently polyarticular [24]. Of transplant patients 13%
will experience new-onset gout, and as many as 50% will
become hyperuricemic [25]. Among patients receiving heart
transplants rates of hyperuricemia are as high as 81%, with
8–12% experiencing new-onset gout [24].
Kidney transplant recipients may develop increased levels of
uric acid because its secretion diminishes with the
decreasing glomerular filtration rate [26]. Pharmaceutical
agents that are commonly prescribed to transplant recipients –
including diuretics, antimicrobials such as ketoconazole,
ethambutol and pentamidine, and certain immunosuppressive
agents such as cyclosporine – are strongly associated with
hyperuricemia and gout [27].
Cyclosporine, a calcineurin inhibitor, is thought to increase
uric acid levels by reducing tubular uric acid secretion and
inhibiting glomerular filtration rates because of its ability to
increase renal arterial vasoconstriction [28,29]. A study
conducted by Lin and coworkers [30] examined the frequency
of hyperuricemia and gout in renal transplant patients who
were treated with either cyclosporine and prednisone or
azathioprine and prednisone. Hyperuricemia was significantly
more common among patients who received cyclosporine
than among those who received azathioprine (84% versus
30%; P = 0.0001), as was gout (7% versus 0%). Progression
from acute gout to chronic, tophaceous gout can occur in as
fewer as 6 months in some transplant patients.
The immunosuppressive agent tacrolimus has the potential to
increase uric acid through its effect on glomerular filtration
rate [31]. However, studies suggest that hyperuricemia
occurs in under 3% of patients who receive tacrolimus, and
so transplant recipients who receive this agent may be at
lower risk for gout than those who receive cyclosporine.
Diet and alcohol intake
The association of purine-rich foods (e.g. meat, seafood,
purine-rich vegetables such as peas, beans, and lentils), high
protein intake, and dairy intake was examined in a study
conducted by Choi and coworkers [32] in 47,120 men who
had no history of gout at baseline. During 12 years of follow
up, 730 confirmed new cases of gout were documented. Diet
was assessed using the Willett Food Frequency
Questionnaire, an instrument that is the ‘gold standard’ in
nutritional epidemiology. Increased meat and seafood intake
were associated with 1.41-fold and 1.51-fold increases in risk
for gout, respectively, for the highest versus the lowest
quintiles of intake. No increase in risk for gout was associated
with the intake of purine-rich vegetables or total protein
intake. The risk for gout was reduced by nearly 50% in
persons in the highest quintile of dairy intake compared with
those in the lowest quintile. The majority of these
associations were independent of body mass index (BMI),
older age, hypertension, alcohol use, diuretic use, and
chronic renal failure. Although it was not surprising that meat
and seafood had significant associations with the incidence
of gout, the lack of effect of purine-rich vegetables in
predisposing to gout was a more novel finding. It was also
notable that there was a 50% reduction in gout incidence
among those consuming the most dairy products (particularly
low-fat dairy products).
Alcohol consumption, particularly consumption of purine-rich
alcoholic beverages such as beer, is also correlated with an
increase in the risk for hyperuricemia. In a second report by
Choi and coworkers [33], and including the same cohort as
in the previously cited report, a dose–response relationship of
alcohol consumption to gout risk was found, after adjusting
for other potential confounders. Beer consumption and, to a
lesser extent, liquor consumption was shown to increase a
person’s risk for gout. It should be noted that beer is rich in
guanosine, and this was thought to provide a biologic basis
for this association. Of note, wine was not a significant risk
factor for gout. Although the investigators did an excellent job
of accounting for potential confounders, there are clear
differences between people who consume wine and those
who consume beer and mixed drinks, and the possibility for
unmeasured confounding persists. However, adding to the
strength of these findings, a subsequent investigation by
Choi and Curhan [34] evaluated the relationship between
intakes of beer, liquor, and wine and serum uric acid levels
using data from 14,809 participants in the Third National
Health and Nutrition Examination Survey (NHANES). Both
before and after adjustment for other risk factors for
hyperuricemia, beer and liquor intake was positively
associated with increased serum urate levels (P for trend
< 0.001). In contrast, wine intake was significantly associated
with reduced serum urate before, but not after, adjustment for
other risk factors.
Obesity
Obesity is a growing epidemic in the USA. Presently,
approximately 60% of Americans are overweight, and
childhood obesity is increasing at an alarming rate [35]. BMI
Available online http://arthritis-research.com/content/8/S1/S2is significantly associated with risk for gout: compared with
persons with a BMI of 21–22.9 kg/m2, the age-adjusted
relative risk for gout is 1.40 for a BMI of 23–24.9 kg/m2, 2.35
for a BMI of 25–29.9 kg/m2, 3.26 for a BMI of 30–
34.9 kg/m2, and 4.41 for a BMI of 35 kg/m2 or higher [15].
Weight gain over time is also associated with risk for gout,
even after adjusting for initial weight and other risk factors.
Data suggest that obesity increases serum urate by eliciting
both increased production and decreased renal excretion of
urate [36]. In the Normative Aging Study [37], weight gain
between the first and third visits was positively associated
with increases in serum urate. In contrast, weight reduction
has been shown in prospective studies to be associated with
declines in uric acid levels [38].
Gout and chronic disease associations
A number of diseases have a strong association with gout.
This raises the question of cause and effect – do these
conditions result from gout, or do these diseases predispose
individuals to gout?
The metabolic syndrome
The recent increase in the prevalence and clinical complexity
of gout may partly be attributable to hyperuricemia associated
with the metabolic syndrome, a clinical entity that is mediated
primarily by insulin resistance. The majority of obese patients
meet the criteria for metabolic syndrome, which is
characterized by a clustering of central obesity; dyslipidemia
(hypertriglyceridemia and low high-density lipoprotein [HDL]
cholesterol); hypertension (≥130/85 mmHg); insulin resis-
tance, glucose intolerance, or type 2 diabetes mellitus; hyper-
uricemia; and a prothrombotic and proinflammatory state
[39]. In an analysis of data from 8814 men and women aged
20 years or older, the age-adjusted prevalence of the meta-
bolic syndrome was 23.7% from 1988 to 1994 [40]. The
prevalence of the metabolic syndrome also varied by
ethnicity; for example, among Mexican Americans the age-
adjusted prevalence of the metabolic syndrome is 31.9%
[41]. Given that the incidence of obesity is rapidly increasing,
it is likely that the prevalence of the metabolic syndrome has
grown substantially in the intervening decade since these
data were recorded.
Components of the metabolic syndrome have been
associated with hyperuricemia. In a cross-sectional study
conducted in 4053 African-American and Caucasian adults
[14], BMI, fasting insulin, and triglycerides were significantly
higher, and HDL-cholesterol was significantly lower in male
and female individuals with hyperuricemia. BMI had the
strongest correlation with urate among the metabolic syn-
drome components. Insulin resistance was also associated
with serum urate levels. However, the influence of fasting
insulin was not as strong as that of obesity. After controlling
for obesity, insulin, and the other components of the
metabolic syndrome, male persons with high triglycerides
were more likely to have hyperuricemia. These data suggest
that the relationship between hyperuricemia and the meta-
bolic syndrome may result predominantly from the co-variation
of these conditions with adiposity and secondarily with insulin
level, and – at least in men – elevated triglycerides.
Hypertension
The relationship between hyperuricemia and hypertension is
notable, because a higher serum urate level is known to be
associated with hypertension. As many as 50% of untreated
hypertensive persons have hyperuricemia, which often
precedes hypertension, and even among children hyper-
uricemia has been shown to correlate with blood pressure. In
the Normative Aging Study [1], gout was found to be more
common among hypertensive individuals, with a strong
association with thiazide diuretic use. One issue is whether
thiazide diuretics confound the drug effect with hypertension.
Sanchez-Lozada and coworkers [42], in their examination of
the afferent arterioles in a rat model of gout, found that high
urate levels may induce vascular effects that can be
attenuated with the use of allopurinol, suggesting grounds for
biologic plausibility for this observational association.
Cardiovascular disease
Irrespective of the outcomes of cardiovascular disease (CVD)
such as coronary heart disease, ischemic heart disease, new
cardiovascular events, or even cardiovascular mortality, CVD
is strongly associated with gout. Two large US cohorts that
have been rich resources for epidemiologic investigation are
the Framingham study and NHANES, which have reached
somewhat different conclusions on the associations between
cardiovascular events and gout.
Using Framingham data, Culleton and coworkers [43]
showed that serum urate levels were not independently
associated with CVD, after adjustment for other risk factors.
That study suggested that diuretic use, more than gout, was
associated with CVD. According to NHANES data [44], the
risk for death due to ischemic heart disease increased 1.77-
fold in men and 3-fold in women when comparing the highest
quartile with the lowest quartile for serum urate. For each
59.5  µmol/l increase in uric acid level, cardiovascular and
ischemic heart disease mortality increased. After stratification
by cardiovascular risk status, diuretic use, and menopausal
status, the relationship between serum urate levels and
cardiovascular mortality remained significant except among
men using diuretics and men with more than one
cardiovascular risk factor. It has been argued that NHANES is
a more generalizable cohort than Framingham because it
represents a wider spectrum of the US population. However,
the Framingham study showed that serum urate may be a
confounder for both hypertension and diuretic use, which has
called the NHANES data into question.
Recent clinical trial data add fuel to this controversy. In the
Losartan Intervention For Endpoint reduction in hypertension
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associated with a 1.02-fold increase in the risk for cardio-
vascular events per 10 µmol/l increase; this association was
significant in women but not in men.
Lifestyle modifications for gout
The data presented above reveal a clear relationship between
diet and lifestyle and the development of hyperuricemia and
gout. As metabolic disorders, hyperuricemia and gout are
often amenable to changes in diet, lifestyle, and medication.
As more data on the modifiable risk factors and co-
morbidities of gout become available, integration of these
data into gout management strategies may become essential,
similar to the current management strategies for hypertension
[46] and type 2 diabetes [47]. These lifestyle modifications
are inexpensive and safe and, when combined with drug
therapy, may result in better control of this disorder.
The lifestyle modification recommendations for the treatment
or prevention of gout are similar to those for the prevention or
treatment of other major chronic disorders [48,49] (Fig. 2).
Thus, the net health benefits from these general lifestyle
recommendations [49] are expected to be even greater
among patients with gout, particularly those with coexisting
insulin resistance syndrome, diabetes, obesity, and hyper-
tension [48]. In particular, weight control, reduced consump-
tion of red meat, and daily exercise are important lifestyle
modifications for patients with gout or hyperuricemia and
parallel recommendations for the prevention of coronary heart
disease, diabetes, and certain types of cancer. Available
open-label, interventional data suggest that weight reduction
is associated with a decline in uric acid levels [36,38].
Furthermore, data on the relationship between purine-rich
foods and urate levels indicate that restricting purine intake
can reduce serum uric acid levels. For example, substitution
of a purine-free formula diet over a period of days was shown
to reduce the blood uric acid of healthy men from an average
of 5.0 mg/dl to 3.0 mg/dl [50,51]. In general, dietary
restriction of purine-rich foods lowers urinary excretion of uric
acid by about 200–400 mg/day and decreases mean serum
urate levels by about 1–2 mg/dl [52]. Thus, reducing intake of
purine-rich foods, particularly those of animal origin such as
red meat, is recommended in the prevention and manage-
ment of hyperuricemia and gout. Red meat is also the main
Available online http://arthritis-research.com/content/8/S1/S2
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Figure 2
Dietary influences on the risk for gout and their implications within a Healthy Eating Pyramid. Data on the relationship between diet and the risk for
gout are primarily derived from the recent Health Professionals Follow-Up Study [15,32,33]. Upward solid arrows denote an increased risk for
gout, downward solid arrows denote a decreased risk, and horizontal arrows denote no influence on risk. Broken arrows denote potential effect but
without prospective evidence for the outcome of gout. Adapted from [48]. Copyright 2005 with permission from American College of Physicians.source of saturated fats, which are positively associated with
insulin resistance [53,54], which in turn is closely associated
with gout. These fats also increase low-density lipoprotein
cholesterol more than HDL-cholesterol, resulting in an overall
negative health effect. Increased consumption of red meat
and saturated fats has been linked to major disorders such as
coronary artery disease, type 2 diabetes, and certain types of
cancer. Thus, it is important for patients with gout to limit red
meat consumption, as is indicated by the new Healthy Eating
Pyramid recommendations for the general public (Fig. 2) [49].
For cardiovascular benefit, instead of consuming fish,
patients with gout could consider taking plant-derived ω3
fatty acids or eicosapentanoic acid and docosahexanoic acid
supplements. Experimental evidence also suggests that diets
enriched with γ-linolenic acid and eicosapentaenoic acid
significantly reduce urate crystal induced inflammation;
however, the effect of such a diet on the clinical course of
gout has not yet been studied [55].
The recent recommendations on dairy consumption for the
general public may be applicable in most patients with gout
or hyperuricemia, and may offer additional benefit to those
individuals with hypertension, diabetes, and cardiovascular
disorders [32,56]. Further risk–benefit assessments in specific
clinical contexts would be helpful. Daily consumption of nuts
and legumes, as recommended by the Harvard Healthy
Eating Pyramid [49], may also provide important health
benefits without increasing the risk for gout [32]. New data
on the incidence of gout suggest that a daily glass of wine
might provide health benefits without raising the risk for gout,
as opposed to beer or liquor consumption [33,57]. However,
reducing or eliminating alcohol – particularly purine-rich
beverages such as beer and certain liquors – is generally
recommended due to the significant effect on uric acid levels.
Several studies have suggested that high doses of vitamin C
have a uricosuric effect [58-62]. For example, one study [61]
showed that ingestion of 4.0 g ascorbic acid led to a twofold
increase in fractional clearance of uric acid up to 6 hours
after ingestion, and that ingestion of 8.0 g ascorbic acid for
3–7 days reduced serum uric acid by up to 3.1 mg/dl as a
result of sustained uricosuria. A recent trial indicated that
taking 500 mg/day vitamin C for 2 months reduced serum
uric acid by 0.5 mg/dl [62]. Because vitamin C is generally
considered safe, its uricosuric effect may provide a potentially
useful option for the prevention and management of
hyperuricemia and gout.
Conclusion
Emerging data on the epidemiology of gout suggest that the
prevalence of gout is rising. Advancing age increases the
prevalence of gout; this is partly attributable to the increased
risk factors for gout – including metabolic syndrome, hyper-
tension, and renal disease – that are associated with age.
New data is emerging on risk factors for gout, and of note is
the increasingly strong association of hyperuricemia with both
hypertension and CVD.
The increasing prevalence of gout worldwide indicates that
there is an urgent need for improved efforts to identify
patients with hyperuricemia early in the disease process and
before the clinical manifestations of gout become apparent.
Lifestyle modifications, including weight loss, dietary
changes, hypertension control, and changes in medication
regimens, may provide adequate control of hyperuricemia in
some patients, particularly when they are instituted early in
the course of disease; they may also result in better control of
gout in other patients when combined with drug therapy.
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